Renalytix plc
("Renalytix" or the "Company")

Publication of Annual Report 2024 and Notice of 2024 Annual General Meeting

LONDON and NEW YORK, 26 November 2024 Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that the Annual Report for the year ended 30 June 2024 and the Notice of 2024 Annual General Meeting ("AGM") have now been published on the Company's website (https://investors.renalytix.com/financials-and-filings/annual-and-half-year-reports and https://investors.renalytix.com/news-and-events/documents-and-presentations), and posted to shareholders who have not consented to receive electronic communications.

The AGM will be held in-person on 19 December 2024 at 11.00 (GMT) at 6 Stratton Street Mayfair, London W1J 8LD.

To help with practical arrangements for the AGM, any shareholder wishing to attend is requested to register first by contacting Walbrook PR via email at renalytix@walbrookpr.com or by telephone at +44 (0)20 7933 8780.

For further information, please contact:

Renalytix plc	www.renalytix.com
James McCullough, CEO	**Via Walbrook PR**
Stifel (Nominated Adviser, Joint Broker)	**Tel: 020 7710 7600**
Nicholas Moore / Nick Harland / Ben Good	
Oberon Capital (Joint Broker)	**Tel: 020 3179 5300**
Mike Seabrook / Nick Lovering	
Walbrook PR Limited	**Tel: 020 7933 8780** or renalytix@walbrookpr.com
Paul McManus / Alice Woodings	Mob: 07980 541 893 / 07407 804 654
CapComm Partners	
Peter DeNardo	**Tel: 415-389-6400** or investors@renalytix.com

About Renalytix
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

END

NOAEANFSAEXLFFA